Printed From BioPortfolio.com
Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial
00:01 EST 11 Jan 2018 | 2 Minute Medicine
1. Osimertinib demonstrated a significantly longer duration of progression-free survival compared to standard of care epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKI) in patients with untreated EGFR-mutated locally-advanced or metastatic non-small-cell lung cancer (NSCLC). 2. Osimertinib treated patients had fewer grade 3 or higher adverse events compared to patients treated with standard EGFR-TKI therapy. […]
Original Article: Osimertinib improves progression-free survival in EGFR-mutated non-small-cell lung cancer: The FLAURA trial
